Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA progress, and launch potential by 2026.

Anito-cel’s Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its therapy candidate anito-cel for the treatment of multiple myeloma. The ...

Philippine indie game developer Anino Entertainment has today announced the launch of Anito: Defend a Land Enraged. The adventure role-playing game, which was recently confirmed as a finalist in ...

Anito-cel is a BCMA CAR T that utilizes a novel binder (or CAR) known as the D-Domain. Its small size (8kDa) facilitates high T-cell transduction and expression, resulting in more CAR positive ...

The process of turning a patient’s immune cells into a living drug isn’t always successful, but Arcellx said anito-cell was successfully manufactured for 99% of patients in its studies. Kite ...

Anito will be coming out in the UK, Belgium, the Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, and Russia. We're also looking for a distributor in the US and other territories.

Anito: Defend A Land Enraged The first Filipino-made PC game is finally here!. After two years of waiting, Philippine indie game developer Anino Entertainment is proud to launch its pioneering ...

Anito: Defend a Land Enraged Mini-Review at Gameshark In the main, a recommending write-up for developer Anino's isometric perspective genre-crossing title ...

Anito: Defend a Land Enraged is the very first Filipino developed computer game. Seeing its development on various computer and tech shows in the Philippines it made me enthusiastic to actually ...